BioSpace News Archive

Harmony Biosciences Holdings, Inc. today announced that Harmony’s management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences.

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for the latest release of Rapid ICH — the best performing intracranial hemorrhage (ICH) triage and notification product on the market with a sensitivity of 97% and specificity of 100%.

Kinimmune, Inc. announced that the company has received $400k in funding from the National Cancer Institute at the National Institutes of Health for its Phase I STTR application, “Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers”.

Edgewise Therapeutics, Inc. announced that members of its senior management team will participate in the following upcoming investor conferences.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the commencement of production of its EsoCheck® Esophageal Cell Collection Devices (“EsoCheck”) at Coastline International, Inc. (“Coastline”), a high-volume manufacturer headquartered in San Diego, CA with plants in Mexico.

Nanomix Corporation, a leader in the development of mobile, affordable, point-of-care diagnostics, announced that it has entered into an exclusive distribution agreement with Woodley Equipment Company, Ltd., a global veterinary distributor.

Halozyme Therapeutics, Inc. announced that members of its management team are scheduled to present and host investor meetings at the following investor conferences.

Brand Institute is proud to announce its work with CMP Pharma in developing the brand name TADLIQ®, for tadalafil oral suspension, which was approved by the FDA on June 17, 2022.

Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer.